The New Money
Posts
Johnson & Johnson's DMT Deal, The NYSE Selects Avalanche, And Hims Makes A Peptide Push

Johnson & Johnson's DMT Deal, The NYSE Selects Avalanche, And Hims Makes A Peptide Push

The markets and trends that matter, made simple. Discover what’s next.

November 10, 2026

Johnson & Johnson Co-Leads $100 Million Round For Psychedelic Drug Developer

Johnson & Johnson's (NYSE: JNJ) venture capital arm co-led a $100 million Series C financing round for Delix Therapeutics, marking their first ever investment in a psychedelic drug development company. Delix Therapeutics is currently developing an oral non-hallucinogenic 5-MeO-DMT analog drug which is entering a Phase II clinical trial.

The NYSE Selects Avalanche For Tokenized Stock Settlement

The New York Stock Exchange selected Avalanche as the sole settlement ledger for their planned tokenized stock platform, which they are aiming to operate 24/7 and enable instant settlement on trades pending regulatory approval.

Neuroscientist Andrew Huberman Joins Hims & Hers Health For Push Into Peptides

Neuroscientist and Stanford professor Andrew Huberman officially joined the board of directors of Hims & Hers Health (NYSE: HIMS) and will work closely together on shaping the clinical standards and testing for their new Peptides+ offering.

There’s A New Opportunity In Mobile Power Infrastructure

Electricity demand in North America is growing faster than the grid can expand. Which is exactly why NOMAD Power Solutions (NASDAQ: NMAD) is deploying mobile energy infrastructure that can be used by utilities, oil and gas operators, EV charging networks and data centres.

The Sprint

IBM (NYSE: IBM) successfully deployed a Quantum System Two with their 120-qubit Nighthawk r2 processor at the University of Chicago’s Hyde Park Labs
AST SpaceMobile (NASDAQ: ASTS) and Rakuten formed a new joint venture known as Rakuten AST to build a satellite network in Japan that connects directly to ordinary smartphones.
The United States Nuclear Regulatory Commission approved a construction permit for four X-energy (NASDAQ: XE) Xe-100 small modular reactors at Dow’s (NYSE: DOW) chemical plant located in Seadrift, Texas.
argenx (NASDAQ: ARGX) entered into a definitive agreement to acquire oral-peptide discovery company Unnatural Products for up to $1.15 billion.

Looking to connect? Reach out and get in touch.

New here? Join our community of 100,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.